Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK3 | Q13188 | 12/20 | 1.00 |
| ▸ | STK4 | Q13043 | 11/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 17/20 | 0.74 |
| ▸ | CDC7 | O00311 | 1/20 | 0.54 |
| ▸ | ROS1 | P08922 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | MARK3 | P27448 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | CDK8 | P49336 | 1/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.54 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.54 |
| ▸ | MELK | Q14680 | 1/20 | 0.54 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.54 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.54 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.54 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30295892 | 0.91 | STK4 (1.00) | STK3STK4LRRK2 | |
| SCHEMBL31301604 | 0.87 | LRRK2 (0.98) | STK3STK4LRRK2CDC7ROS1 | |
| SCHEMBL31301676 | 0.87 | LRRK2 (0.93) | STK3STK4LRRK2CDC7ROS1 | |
| SCHEMBL30295756 | 0.86 | LRRK2 (0.79) | STK3STK4LRRK2CDC7ROS1 | |
| SCHEMBL3953561 | 0.85 | LRRK2 (1.00) | STK3STK4LRRK2CDC7ROS1 | |
| SCHEMBL30295837 | 0.85 | STK4 (0.76) | STK3STK4LRRK2 | |
| SCHEMBL30295709 | 0.85 | STK4 (0.75) | STK3STK4LRRK2 | |
| SCHEMBL15401357 | 0.84 | LRRK2 (1.00) | STK3STK4LRRK2 | |
| SCHEMBL31301647 | 0.84 | LRRK2 (0.82) | STK3STK4LRRK2CDC7MARK3 | |
| SCHEMBL31301736 | 0.83 | LRRK2 (0.74) | STK3STK4LRRK2CDC7ROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | STK3, STK4, STK36 | STK3 1/4885STK4 2/4885LRRK2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.